论文部分内容阅读
随着基因表达谱与基因芯片技术的开展,乳腺癌在分子水平上表现出的高度异质性也逐渐受到关注。不同分子分型的乳腺癌,其流行病学危险因素、疾病自然进展过程以及对全身或局部治疗的反应性都不尽相同;对于乳腺癌的准确分型能够较为精确地反映肿瘤的生物学行为,对于判断预后、制定更具个体化的治疗策略具有深刻的意义。2011年的St.Gallen共识已针对不同的乳腺癌分子分型给出了原则性的治疗建议,标志着乳腺癌的治疗已逐步进入了在规范化多学科综合治疗模式的基础上,倡导个体化治疗的时代。
With the development of gene expression profiling and microarray technology, the high heterogeneity of breast cancer at the molecular level is also receiving increasing attention. Different types of breast cancer, its epidemiological risk factors, the natural progression of the disease and the response to systemic or local treatment are not the same; accurate classification of breast cancer can be more accurately reflect the biological behavior of the tumor , To determine the prognosis, the development of a more personalized treatment strategy has profound significance. The 2011 St.Gallen Consensus has provided principled treatment recommendations for different breast cancer molecular subtypes, indicating that the treatment of breast cancer has gradually entered the standardization of multi-disciplinary treatment based on the model, advocating individualized treatment Era.